Pharmaceuticals
Advent buys majority stake in US, China-based BioDuro
Advent International has acquired a majority stake in BioDuro, a pharmaceutical contract research and development organization (CRO) with operations in the US and China, from the Bridgewest Group conglomerate.
Immunochina secures $20.5m Series C round
Beijing-based Immunochina Pharmaceuticals has closed a RMB140 million ($20.5 million) Series C round with support from a group of investors including PayPal co-founder Peter Thiel.
Shanghai launches $7.35b biotech fund
The Shanghai government has launched a biotech sector-focused fund targeting a hard cap of RMB50 billion ($7.35 billion) in partnership with Guotai Junan Securities, China Pacific Insurance and Shanghai Zhangjiang Group.
China’s MabPlex raises $59m Series A
Shandong province-based biologics and biopharmaceutical contract development and manufacturing organization (CDMO) MabPlex has raised RMB400 million ($59 million) in Series A funding led by SDIC Venture Capital and Shenzhen Capital Group.
Eight Roads invests $31m in Indian pharma player
Eight Roads Ventures, the proprietary investment arm of Fidelity International, has invested INR2.18 billion ($30.6 million) in Indian pharmaceutical manufacturer Caplin Point. Sister fund F-Prime Capital Ventures also participated.
Fund focus: Sizing up selectively
ChrysCapital Partners has increased its fund size and its commitment to operations in response to a maturation of the Indian market characterized by bigger deals and more opportunities to drive change
US, China-based Apollomics raises $100m Series B
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
Chinese gene therapy player raises $45m
New Alliance Capital has led a $45 million Series A round for China-based contract research and manufacturing services provider Thousand Oaks Biopharmaceuticals, with participation by Addor Capital and several other healthcare-focused investors.
Iron Pillar leads $22m round for India's Vyome Therapeutics
Indian venture capital firm Iron Pillar Capital Management has led a $22 million Series D round for Vyome Therapeutics, a domestic pharmaceuticals developer focused on skin diseases.
Advantech leads $55m round for China biotech player
Advantech Capital has led a $55 million Series B funding round for China’s Connect Biopharmaceuticals with support from Qiming Venture Partners.
Actis exits India's Symbiotec to MOPE, Invascent
Motilal Oswal Private Equity (MOPE) and healthcare-focused GP Invascent Capital have invested in Indian pharmaceutical developer Symbiotec Pharmalab, providing an exit for Actis Capital.
Fosun-owned Henlius Biotech files for Hong Kong IPO
Shanghai Henlius Biotech, a Chinese drug developer controlled by Fosun Group, has filed for a Hong Kong IPO. Third-party investors include Loyal Valley Capital and China International Capital Corporation (CICC).
CX buys stake in India's Veeda Clinical Research
CX Partners has led a consortium of private equity investors to commit an undisclosed sum to Indian contract research organization Veeda Clinical Research.
China's Alphamab gets $100m Series A
China’s Alphamab Oncology has completed a $100 million Series A funding round from a group of investors including PAG Growth Capital, Advantech Capital, and OrbiMed.
Hillhouse co-leads $93m Series B for US biotech firm
Hillhouse Capital and Quan Capital have led a $93 million Series B round for NextCure, a US-based biopharmaceutical company focused on cancer and other diseases.
PE-backed CStone files for Hong Kong IPO
CStone Pharmaceuticals, a cancer-focused Chinese biopharmaceutical developer with a number of PE and VC backers, has filed for an IPO in Hong Kong.
Deal focus: XtalPi takes big pharma into the cloud
China and US-based XtalPi has raised $61 million this year from investors impressed its use of quantum physics, computational chemistry, and artificial intelligence to bring greater certainty to drug development
US, China-based Terns Pharma secures $80m Series B
Vivo Capital and Orbimed have co-led an $80 million Series B funding round for US and China-based Terns Pharmaceuticals.
US-China biotech: Troubled transfers
Chinese investment in US biotech – and its ability to import intellectual property for domestic drug development – looks set to be a casualty of worsening relations between the two nations
Wilmar Ventures backs Alzheimer's specialist Accera
Wilmar Ventures, an investment arm of Asian agribusiness conglomerate Wilmar International, has led a $50 million funding round for Accera, a developer of treatments for Alzheimer’s disease.
Eight Roads leads Series C for India's PharmEasy
Indian online pharmacy PharmEasy has raised a $50 million Series C funding round led by Eight Roads Ventures, the proprietary investment arm of Fidelity International.
Carlyle invests in Chinese pharma industry supplier
The Carlyle Group has paid an undisclosed sum for a significant minority stake in Ambio, a US-based pharmaceuticals company with substantial operations in China.
China's Jianke raises $130m Series B
Chinese online pharmacy operator Jianke has closed a $130 million Series B funding round led by healthcare-focused GTJA Investment Group.